In a retrospective review of 24 patients with histoplasmosis, blastomycosis, or coccidioidomycosis treated with voriconazole (most for salvage therapy), outcome was favorable (improved or stable) in 22 (95.8%) within two months of starting voriconazole and 20 (83.3%) at last follow-up. Prospective studies are required to determine its role for treatment of endemic mycoses.
Endemic fungal infections in the United States, due to Histoplasma capsulatum, Blastomyces dermitiditis and Coccidioides immitis are generally treated with amphotericin B forumulations, itraconazole or fluconazole. (6, 9, 27) Each of these standard antifungals has limitations that preclude use in some patients. Renal and infusional toxicities associated amphotericin B formulations, and gastrointestinal absorption and intolerance difficulties with oral itraconazole, are most notable.
Voriconazole is a well-tolerated, orally bioavailable newer triazole antifungal with a broad range of activity against a variety of yeasts and moulds. (22) Although primarily indicated for treatment of Aspergillus infections, voriconazole is also active in vitro against H. capsulatum, B. dermatitidis and Coccidioides species (10, 13, 20, 26) .
However, except for a few case reports, clinical studies have not been performed evaluating voriconazole for treatment of endemic mycoses in humans.
We undertook a retrospective chart review of 24 patients with endemic fungal infection who were treated with voriconazole between January 1, 2001 and May 30, 2005, at eight tertiary care centers. Five of the cases were previously reported (8, 12, 19) . The study was approved by the institutional review committee at each institution.
Fifteen of 24 patients were male and the mean age was 45 years. Nine were solid organ transplant recipients, one an allogeneic stem cell transplant recipient, six had other chronic diseases and eight had no underlying disease (Table 1) . Diagnostic criteria were modifications of previously published definitions of fungal infection in immunocompromised hosts (3, 17) . Diagnosis of endemic fungal infection was for CNS blastomycosis, as well as for CNS histoplasmosis; azoles should be reserved for salvage therapy as in the cases reported herein. (6, 27) Voriconazole is active in vitro against Coccidioides spp. exhibiting susceptibility patterns comparable to those seen with Blastomyces dermatitidis and Histoplasma capsulatum (13) . Furthermore, in vitro susceptibility to voriconazole was somewhat better than to itraconazole. Voriconazole has not been studied in an animal model of coccidioidomycosis but it has been used successfully in a few patients (2, 18, 19) .
In this report, six of the seven patients with coccidioidomycosis who were treated with voriconazole, after other antifungal toxicity/intolerance or for physician preference, Alive ( 
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